On October 16, 2025 Laverock Therapeutics reported that it has been awarded a prestigious Biomedical Catalyst award, consisting of a £500k grant, as part of the 2024 funding competition from Innovate UK, the UK’s innovation agency. The award will allow Laverock to further progress its next generation gene control platform and anti-cancer macrophage cell therapeutics for hard-to-treat cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Laverock’s proprietary platform for controlling gene expression via micro-(mi-) RNA recoding enables development of programmable cell-based therapeutics with improved efficacy and safety over the current state of the art. In a new concept to be developed, the Biomedical Catalyst award will be used to validate a more versatile approach to harnessing the activation of these non-coding miRNAs in functional cell states. Validation will come from assessing the programmed cells with a suite of laboratory based, human disease representative model systems.
Support from Innovate UK and the Biomedical Catalyst for this project will result in extension to Laverock’s platform capabilities, configured on harnessing the intrinsic biology of miRNAs, while further strengthening the company’s internal capabilities in immune oncology. Consequently, project output will facilitate development and nomination of future oncology therapeutic candidates.
Vlad Seitan, Chief Scientific Officer of Laverock Therapeutics, said, ‘We’re tremendously excited by this Biomedical Catalyst award and the public endorsement of our approach that Innovate UK funding provides. We’d like to thank Innovate UK for their support and look forward to integrating our novel programmable gene silencing platform into more effective therapeutic designs for the benefit of the global cancer patient community.’
This award complements the company’s recent expansion of its seed funding round to £20m.
(Press release, Laverock Therapeutics, OCT 16, 2025, View Source [SID1234668716])